Status:
COMPLETED
Defining N-Acetyl Cysteine as a Treatment for Inhibiting Prurogenic Stimuli
Lead Sponsor:
Wright State University
Conditions:
Pruritus
Skin Disorder
Eligibility:
All Genders
18-40 years
Phase:
EARLY_PHASE1
Brief Summary
The objective of this double-blinded placebo-controlled cross-over study is to define the role of the over the counter agent, N-acetyl cysteine (NAC), in mitigating the development of pruritus (skin i...
Eligibility Criteria
Inclusion
- Males and Females
- All skin types (Fitzpatrick types I - VI)
- Age 18 - 40
- Able to comprehend procedures and risks
Exclusion
- Currently taking immunosuppressive or immunomodulating or psychotropic medications.
- This includes antihistamines and aspirin-like anti-inflammatory medications (NASIDs) for the past month.
- History of peripheral neuropathy, Charcot-Marie-Tooth, familial dysautonomia or heavy metal toxicity
- History of gastrointestinal abnormalities (including irritable bowel syndrome)
- History of inadequately controlled Diabetes Mellitus
- History of abnormal scarring
- History of skin infections within 6 weeks
- History of skin disease (atopic dermatitis, psoriasis, xerosis) or "sensitive skin"
- Pregnancy or nursing
- Other serious health issues, including liver or kidney disease
Key Trial Info
Start Date :
June 19 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 4 2024
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT05287724
Start Date
June 19 2022
End Date
January 4 2024
Last Update
March 6 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Wright State Physicians
Fairborn, Ohio, United States, 45324